Humacyte, Inc. (HUMAW) Stock Price & Analysis
Humacyte, Inc. (HUMAW) rose 0.00% to USD 0.06 as of June 10, 2026 at 14:26 UTC, according to Nexqual real-time market data.
HUMAW last closed at USD 0.06; the session ranged USD 0.06–0.06 on volume of 250 shares. Market capitalization is —, with a 52-week range of USD 0.06–0.06 (NMS). Source: Nexqual, June 10, 2026 at 14:26 UTC.
Key Statistics (as of June 10, 2026 at 14:26 UTC)
| Price | USD 0.06 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.06 |
| Open | USD 0.23 |
| Day Range | USD 0.06 – 0.06 |
| 52-Week Range | USD 0.06 – 0.06 |
| Volume | 250 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (HUMAW)
Nexqual's technical model rates HUMAW "SELL" based on 2 bullish and 4 bearish signals across 66 daily candles, as of June 10, 2026 at 14:26 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0.11) |
| MACD | 0 (negative) |
Analyst Ratings (HUMAW)
Wall Street analysts rate HUMAW "None", per Nexqual as of June 10, 2026 at 14:26 UTC.
| Consensus Rating | None |
|---|
Earnings (HUMAW)
| Revenue Estimate | $1.11M |
|---|
Source: Nexqual, June 10, 2026 at 14:26 UTC.
Financials & Fundamentals (HUMAW)
| Total Revenue | $2.02M |
|---|---|
| Revenue Growth (YoY) | -4.30% |
| Gross Margin | +0.00% |
| Operating Margin | -5704.04% |
| Profit Margin | +0.00% |
| ROE | -409.47% |
| Debt / Equity | 572.1 |
| Current Ratio | 3.93 |
| Total Cash | $48.54M |
| Total Debt | $66.50M |
| Free Cash Flow | $-64.81M |
Source: Nexqual, June 10, 2026 at 14:26 UTC.
Financial Health Score (HUMAW)
Nexqual rates Humacyte, Inc.'s overall financial health "Critical" across five dimensions, as of June 10, 2026 at 14:26 UTC.
| Growth | Weak — Revenue -4% YoY (latest Q), declining |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Weak — $49M cash vs $67M debt |
| Cash Flow | Weak — FCF negative: -$65M, burning cash |
| Efficiency | Critical — ROE -409%, ROA -51.5% |
Ownership (HUMAW)
| Float | 190.57M |
|---|
Source: Nexqual, June 10, 2026 at 14:26 UTC.
Leadership (HUMAW)
Humacyte, Inc. is led by Laura E. Niklason (age 62), Founder, President, CEO & Director, per Nexqual as of June 10, 2026 at 14:26 UTC.
| Founder, President, CEO & Director | Laura E. Niklason (age 62) |
|---|---|
| CFO, Chief Corporate Development Officer & Treasurer | Dale A. Sander (age 65) |
| Executive Vice President of Enterprise Planning & Analysis | Lisa Molyneux |
| Executive Vice President Regulatory Affairs & Quality | Heather Connelly |
| Senior Vice President of Business Development | Rick McElheny |
Major Backers & Investors (HUMAW)
Notable institutional backers of Humacyte, Inc. include LPL Financial LLC, Jane Street Group, LLC, Sio Capital Management, LLC, according to Nexqual as of June 10, 2026 at 14:26 UTC.
Active Investors
| Investor | Stake |
|---|---|
| LPL Financial LLC | 5.01% |
| Jane Street Group, LLC | 0.97% |
| Sio Capital Management, LLC | 0.97% |
| Susquehanna International Group, LLP | 0.86% |
| Two Sigma Securities, LLC | 0.81% |
| Wolverine Asset Management, LLC | 0.73% |
| Toronto Dominion Bank | 0.39% |
Source: Nexqual, June 10, 2026 at 14:26 UTC.
From Humacyte, Inc.'s Latest SEC 10-K Filing (filed 2026-03-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
- The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
- It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CELUW | Celularity Inc. | USD 0 | ▼ 51.72% |
| JSPRW | Jasper Therapeutics, Inc. | USD 0.01 | ▼ 33.82% |
| HUMA | Humacyte, Inc. | USD 1.41 | ▲ 2.1% |
| QSIAW | Quantum-Si incorporated | USD 0.01 | ▼ 96.59% |
| SRZNW | Surrozen, Inc. Warrant | USD 0.02 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 14:26 UTC. This page is informational and not investment advice.